Todd C. Davis - 02 Mar 2026 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: LGND
Reported as of: 02 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 27 Mar 2026, 20:33:21 UTC
Prior SEC filing: 18 Feb 2026
Next SEC filing: 12 Jun 2026
Source filing: View source filing
Reporting owner signature: By: /s/ Andrew Reardon, Attorney-in-Fact For: Todd C. Davis

Key filing fact

Todd C. Davis filed Form 4 for LIGAND PHARMACEUTICALS INC (LGND) on 27 Mar 2026.

Key facts

This page summarizes Todd C. Davis's Form 4 filing for LIGAND PHARMACEUTICALS INC (LGND).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 27 Mar 2026, 20:33.

Change

Previous filing in this sequence was filed on 18 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001392029 Primary reporting owner

Davis Todd C

Relationship: Chief Executive Officer, Director
Address: 555 HERITAGE DRIVE, SUITE 200, JUPITER
Signature: By: /s/ Andrew Reardon, Attorney-in-Fact For: Todd C. Davis
Signature date: 27 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LGND transaction

Common Stock

Award

Transaction value
Shares: +10,495
Change %: +5.6%
Price: $0.000000^*
Shares after: 199,381
Date: 02 Mar 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LGND transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value
Shares: +50,058
Change %
Price: $0.000000^*
Shares after: 50,058
Date: 02 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 50,058
Exercise price: $202.55
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest over three years, in three substantially equal annual installments on February 15, 2027; February 15, 2028; and February 15, 2029, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Pursuant to an election under the Issuer's Nonqualified Deferred Compensation Plan, delivery of shares otherwise issuable upon each vesting date will be deferred.

Footnote F2

The Stock Option grant vests and is exercisable as to 12.5% of the underlying shares 6 months after the grant date, and in 42 substantially equal monthly installments thereafter.